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Introduction
In eukaryotic cells, nuclear DNA is organized in a complex
and dynamic structure called chromatin, which allows effi-
cient packaging of the genome and proper chromosomal
segregation during mitosis; chromatin also controls the ge-
nome’s accessibility for essential processes such as replica-
tion, transcription, and repair.1 The basic unit of chromatin
is the nucleosome, in which a stretch of about 147 bp of
DNA wraps around an octamer of the core histones (i.e.,
H2A, H2B, H3, and H4), constituting the nucleosomal
core particle (NCP).2 A number of H1 linker histone iso-
forms bind to short DNA segments at the entry and exit
sites on the surface of the NCP, stabilizing the nucleosomal
structure and contributing to higher-order chromatin
folding.3,4 Although H1 histones have traditionally been
associated with chromatin compaction and a regulatory
function favoring transcriptional repression,5 a more com-
plex and plastic role of these proteins in the control of
accessibility to DNA has gradually been appreciated.6–8 In
mammals, H1 histones are encoded by 11 genes. Among
these, seven are expressed in somatic cells, and the remain-
ing four are transcriptionally active in the germline.3,4 Of
note, even among the seven somatic subtypes, the levels
of these proteins appear to be regulated during the cell cycle
and development, and in different tissues and cell types,
suggesting specific functions for individual isoforms.9 On
the other hand, redundancy in their function has been re-
ported.10,11 In higher eukaryotes, H1 histone isoforms
share a tripartite structure consisting of a central highly
conserved globular domain and two less-conserved, un-
structured N-terminal and C-terminal tails. The globular
domain has high sequence homology among H1 subtypes
and mediates binding to the nucleosome. The two tails
are moderately conserved among orthologs but differ
among isoforms, suggesting functional specificity. Notably,
both tails encompass a number of residues that are sub-
jected to reversiblemodifications with regulatory function.
Among these, the extent of phosphorylation in serine/thre-
onine residues at the C-terminal tail has been proposed to
regulate chromatin dynamics in interphase as well as chro-
mosome condensation during mitosis.4,12
Aberrant histone function, whether due to mutations in
genes coding proteins that participate in histone-modi-
fying complexes or mutations directly affecting histone-
coding genes, has been established as contributing to
oncogenesis and causing multisystem syndromes that
affect growth and cognitive function.13–18 Recently, germ-
line frameshift mutations affecting HIST1H1E (MIM:
142220), which codes a member of the somatic, replica-
tion-dependent linker histone subfamily, have been caus-
ally linked to an as-yet poorly defined syndrome that
includes intellectual disability (ID) (MIM: 617537).19 Mu-
tations were mapped at the C-terminal tail of HIST1H1E
and were predicted to have an equivalent functional
impact by generating the same change in the reading
frame. The five affected individuals belonged to a cohort494 The American Journal of Human Genetics 105, 493–508, Septemof subjects with overgrowth, and were reported to have a
similar facial appearance but variable height, head circum-
ference, and degree of ID.19 Notably, the growth pattern of
these individuals appeared to be complex and character-
ized by a height that was above average during infancy
but that became progressively closer to average over time
until it could be characterized as average or short in adult-
hood. This peculiar pattern of growth has been high-
lighted by a subsequent report, which also confirmed the
association of this class of HIST1H1E mutations with ID
and specific facial features.20
Here, we report that this homogeneous class of disease-
causing frameshift mutations affecting the C-terminal
tail of HIST1H1E results in stable proteins that reside in
the nucleus and bind to chromatin but disrupt proper
compaction of DNA and are associated with a specific
methylation profile. We also provide data indicating that
cells expressing these mutant proteins have a dramatically
reduced proliferation rate and competence, hardly enter
into the S phase, and undergo accelerated senescence.
Remarkably, clinical assessment of 13 newly identified in-
dividuals who are heterozygous for this class of mutations
and of those previously reported allowed us to identify pre-
mature aging as a previously unrecognized feature of the
disorder. Collectively, these data highlight a strict link be-
tween aberrant chromatin remodeling, cellular senes-
cence, and accelerated aging.Material and Methods
Subjects
This study was approved by the Committee for Medical Ethics,
University of Antwerp, Antwerp, and Ethical Committee, Ospe-
dale Pediatrico Bambino Gesù, Rome. Clinical data and DNA spec-
imens from the subjects included in this study were collected
according to procedures conforming to the ethical standards of
the declaration of Helsinki protocols and approved by the review
boards of all involved institutions, and signed informed consent
was obtained from the participating subjects and/or families.
Explicit permission was obtained to publish the photographs of
the subjects as shown in Figure 1.
Exome Sequencing
WES was performed with DNA samples obtained from leukocytes.
In most cases, a trio-based strategy was used. Exome capture was
carried out with the Nimblegen SeqCap EZ Exome v3 (Roche) (sub-
jects 1 and 5), Clinical Research Exome (Agilent) (subjects 2 and 3),
SeqCap EZ VCRome v2.1 (Roche) (subjects 6 and 7), SureSelect Hu-
man All Exon v4 (Agilent) (subjects 8, 9 and 13), SureSelect Hu-
man All Exon v5 (Agilent) (subjects 4 and 12), and SureSelect XT
Human All Exon v6 (Agilent) (subjects 10 and 11) target enrich-
ment kits, and sequencing was performed on HiSeq 2000/2500/
4000 and NextSeq550 platforms (Illumina) through the use of
paired-end reads. WES data processing, sequence alignment to
GRCh37, and variant filtering and prioritization by allele fre-
quency, predicted functional impact, and inheritance models
were performed as previously described.21–27 The de novo origin
of the HIST1H1E frameshifts was confirmed by Sanger sequencing
in all cases.ber 5, 2019
Figure 1. Facial Appearance of Subjects
with HIST1H1E Frameshift Mutations and
Protein Structure
(A) In affected individuals, facial appear-
ance is characterized by a high anterior
hairline, prominent forehead, bitemporal
narrowing, sparse temporal hair, hyperte-
lorism, hooded eyelids, short palpebral fis-
sures, a high and broad nasal bridge, and a
full nasal tip; small, widely spaced teeth;
and low-set ears. A facial appearance
compatible with a more advanced age
(e.g., hypotrichosis and ptosis) is evident
in S1 and S3. (S1, 49 years; S3, 30 years at
last evaluation; S4, 14months; S5, 12 years
at last evaluation; S6, 3 years; S7, 12 years;
S9, 2 years at last evaluation; S11, 6 years at
last evaluation; and S12, 4 years)
(B) Schematic diagram representing the
HIST1H1E structure, which is composed
of a globular domain flanked by N- and
C-terminal tails. The position of the
disease-causing frameshift mutations is
shown above the cartoon. (Novel muta-
tions are highlighted in red.) The number
of independent cases identified in the pre-
sent study is in brackets. The domain
boundaries and cyclin-dependent kinase
phosphorylation sites (black triangles) are
reported below the cartoon. All mutations
are expected to result in a shorter protein
with an identical divergent C-terminal
tail. (The new stop codon is shown below
the cartoon, 194.*)RNA Stability
Total RNA was isolated from circulating leukocytes of subjects 1
and 2 (S1 and S2, hereafter) through the use of the RNeasyMiniKit
(QIAGEN). Reverse transcription was performed with the
SuperScriptIII first strand kit (Invitrogen) according to the manu-
facturer’s instructions. Primer sequences used for RT-PCR are avail-
able upon request.
Constructs
The c.441dupC (p.Lys148Glnfs*48), c.464dupC (p.Lys157Glufs*
39), and c.441_442insCC (p.Lys148Profs*82) were introduced
by site-directed mutagenesis in a HIST1H1E cDNA (RefSeq:
NM_005321.2, NP_005312.1) tagged with Xpress at the N termi-
nus and cloned in pcDNA6/His version C (Invitrogen).
Cell Cultures and Transfections
Skin fibroblasts isolated from skin biopsies (subjects S1 and S2 and
healthy donors), and COS-1 and HeLa lines were cultured in
Dulbecco’s modified Eagle’s medium supplemented with 10%
heat-inactivated fetal bovine serum (GIBCO) and 1% penicillin-
streptomycin, at 37C with 5% CO2.
SCGE Assay
Samples were processed according to the alkaline single-cell gel
electrophoresis (SCGE) assay protocol, as previously described.28The AmericanIn brief, cells were suspended in 0.7% low-melting agarose. Slides
were prepared in duplicates with control cells and fibroblasts
derived from affected individuals placed on opposite sides of the
same slide, immersed in cold lysis solution, and kept at 4C over-
night. After lysis, slides were transferred in alkaline buffer for
20 min. Electrophoresis was carried out for 20 min at 20 V and
300 mA (0.8 V/cm) at 4C. We explored the basal level of nucleoid
relaxation by applying longer electrophoresis run times (40 and
60 min). Slides were neutralized in 0.4 M Tris (pH 7.5) for 5 min,
treated with absolute ethanol, and stored at room temperature.
Slides were then stained with GelRed (Biotium) and scored at a
fluorescencemicroscope (Leica). To evaluate inducedDNA damage
and DNA repair capability, we irradiated fibroblasts with 1 or 2 Gy
g-rays from a 137Cs source at a dose rate of 0.8 Gy/min. During
treatment, cells were maintained at 0C so that DNA repair would
be prevented. The kinetics of DNA repair were assessed by SCGE
assay, as described above. The residual DNA damage was measured
after 15 and 30 min of incubation at 37C. For each experimental
point, at least 75 cells were analyzed.Histone Modifications and Nucleolus Morphology
Assessment
For immunofluorescence, fibroblasts from S1 and control subjects
were seeded at a density of 20 3 103 in 24-well cluster plates onto
12 mm cover glasses. After 24 h of culture in complete medium,Journal of Human Genetics 105, 493–508, September 5, 2019 495
cells were fixed with 3% paraformaldehyde. Following permeabili-
zation with 0.5% Triton X-100 (10 min at room temperature), fi-
broblasts were stained with anti-dimethyl-Histone H3 (lys4) rabbit
polyclonal antibody, anti-trimethyl-histone H3 (lys9) rabbit poly-
clonal antibody, anti-trimethyl-histone H3 (lys27) rabbit poly-
clonal antibody (Millipore), and anti-heterochromatin protein-
1b mouse monoclonal antibody (Chemicon) followed by the
appropriate secondary antibody (Invitrogen) and DAPI. To study
nucleolus morphology, we stained fibroblasts with C23 (MS-3)
mouse monoclonal antibody (Santa Cruz) followed by the appro-
priate secondary antibodies (Invitrogen) and DAPI. Observations
were performed on a Leica TCS SP2 AOBS apparatus. Cells stained
only with the fluorochrome-conjugated secondary antibodies
were used for setting up acquisition parameters. Signals from
different fluorescent probes were taken in sequential scanning
mode, several fields (>200) were analyzed for each labeling condi-
tion, and representative results are shown.Proliferation and Cell-Cycle Assays
Cells were seeded at 200,000 cells per well in a 6-well plate and
incubated a 37C. Cell numbers (mean of three replicates 5 SD)
were counted by trypan blue exclusion after 4 and 7 days. The per-
centages of cells in different cell-cycle phases were determined by
dual flow-cytometry analysis of BrdU-positive cells stained with
the fluorescent DNA probe propidium iodide (PI). In brief, cells
were incubated for 1 hwith BrdU (Sigma Aldrich) at a final concen-
tration of 30 mM. Then BrdU was removed, and cells were rinsed
with PBS, harvested, and permeabilized in ice-cold 100% EtOH.
Cells were incubated with HCl 3N to denature DNA and then
with 0.1 M sodium tetraborate to stop this reaction. Fibroblasts
were incubated with the anti-BrdU antibody (Invitrogen) followed
by goat anti-mouse Alexa Fluor 488 secondary antibody. Finally,
cells were resuspended in a buffer containing 10 mg/mL RNase A
and 20 mg/mL PI and then immediately analyzed through the
use of FACSCalibur (BD Biosciences).SA-b-gal Activity and P53 Evaluation
SA-b-gal activity was assessed as reported.29 In brief, cells were
fixed with 3.6% formaldehyde in PBS for 4 min at room tempera-
ture. Fixed cells were washed and then incubated overnight with
freshly prepared staining solution at 37C in the absence of
CO2. After being washed, the coverslips were mounted with the
antifade Dako fluorescence mounting medium (Agilent Technolo-
gies). P53 endogenous levels were evaluated on fibroblast lysates
collected at different passages using an anti-p53 mouse mono-
clonal antibody (Invitrogen). Membranes were probed with an
anti-GAPDH mouse monoclonal antibody (Santa Cruz) so that
protein content would be normalized.Analysis of Nuclear Morphology
After 24 h of culture in complete medium, fibroblasts were treated
with 2 mM thymidine (Sigma) for 24 h, washed with 13 PBS,
recovered with complete medium for 3 h, and then treated with
100 ng/mL nocodazole (Sigma) for 12 h. Afterward, fresh drug-
free medium was added, and recovery was allowed for 120 min
during which cells were fixed every 15 min in PHEMO buffer for
10 min at room temperature, as previously described.30 Finally,
cells were stained with lamin A/C mouse monoclonal antibody
(Santa Cruz) followed by the appropriate secondary antibody (In-
vitrogen) and DAPI. Observations were performed on a Leica TCS
SP2 AOBS apparatus as described above.496 The American Journal of Human Genetics 105, 493–508, SeptemEvaluation of rRNA Content
Total RNA was extracted from the same amount of control fibro-
blasts and cells derived from affected individuals (400,000 fibro-
blasts) at different cellular passages. Three mL of total RNA was
loaded for size separation on 1% agarose gel and stained with
ethidium bromide.
Evaluation of Protein Stability
COS-1 cells were seeded in 6-well plates the day before transfec-
tion. Cells were transfected at 70% confluency with Fugene 6
transfection reagent (Promega) with wild-type or mutant Xpress-
tagged HIST1H1E expression constructs. Forty-eight h after trans-
fection, cells were treated with cycloheximide (20 mg/mL) for 8
and 16 h or left untreated before lysis. Immunoblotting was per-
formed so that Xpress-tagged HIST1H1E levels could be assessed.
Probing membranes with an anti-GAPDH antibody (Santa Cruz)
allowed normalization of protein content.
CSK Assay
Twenty thousand fibroblasts and 30 3 103 HeLa cells were seeded
on a glass coverslip and maintained in culture complete medium
for 24 h. HeLa cells were transfected with 100 ng of vectors ex-
pressing Xpress-tagged HIST1H1E. Forty-eight h after transfection,
HeLa cells were either fixed with 3% paraformaldehyde or treated
with CSK buffer before being fixed.31 After permeabilization with
0.5% Triton X-100 (for 10 min at room temperature), HeLa cells
were stained with monoclonal antibody to Xpress (Invitrogen)
and then with the appropriate secondary antibody (Invitrogen)
and DAPI for DNA. Analyses were performed in three independent
experiments on a Leica TCS SP2 AOBS apparatus.
Analysis of Cell Morphology
Fibroblasts from subject S1 and a control individual were seeded
in a 100 mm dish cell culture. Optical microscope images at
different passages were taken with Floid Cell Imaging Station
(Life Technologies).
gH2AX Immunofluorescence Staining
Cells were seeded on a glass in a Petri dish for 24 h. The slides were
fixed with 4% paraformaldehyde (Sigma Aldrich), permeabilized
in 0.2% Triton X-100, and blocked in PBS/BSA 1% for 30 min at
room temperature. Slides were incubated with a mouse mono-
clonal anti-phospho-histone H2AX antibody (Millipore) over-
night at 4C, washed in PBS/BSA 1%, and then exposed to the
secondary Alexa 488-labeled donkey anti-mouse antibody (Invi-
trogen, Life Technologies) for 1 h at 37C. After washes in PBS/
BSA, 1% DNA were counterstained with DAPI (Sigma Aldrich) in
Vectashield (Vector Laboratories). Cells were analyzed with fluo-
rescence microscopy using an Axio Imager Z2 microscope (Zeiss).
The frequency of foci per cell was scored in 150 nuclei in two in-
dependent experiments.
Telomere Dysfunction-Induced Foci (TIF) ImmunoFISH
Staining
Cells were seeded on glass slides that were processed as reported for
the gH2AX immunofluorescence staining up to the secondary
antibody (Alexa 488-labeled donkey anti-mouse, Invitrogen).
Immediately after, slides were washed in PBS/Triton X-100
0.05%, fixed in 4% formaldehyde for 2 min and dehydrated
through graded alcohols (70%, 80%, and 100%). Slides and probes
(Cy3 linked telomeric PNA probe, DAKO) were co-denatured atber 5, 2019
80C for 3min and hybridized for 2 h at room temperature in a hu-
midified chamber. After hybridization, slides were washed twice
for 15 min in 50% formamide, 10 mM Tris, pH 7.2, and 0.1%
BSA followed by three 5-min washes in 0.1 M Tris, pH 7.5;
0.15 M NaCl; and 0.08% Tween 20. Slides were then dehydrated
with an ethanol series and air dried. Finally, slides were counter-
stained with DAPI (Sigma Aldrich) in Vectashield (Vector Labora-
tories). Co-localization between gH2AX foci and telomere were
analyzed using an Axio Imager Z2 microscope (Zeiss). The fre-
quency of co-localization dots per cell was scored in 150 nuclei
in two independent experiments.
Quantitative-Fluorescence In Situ Hybridization Analysis
(Q-FISH)
Chromosome spreads were obtained as reported above. Q-FISH
staining was performed as previously described,32 with minor
modifications. In brief, slides and probes (Cy3 linked telomeric,
PANAGENE, and chromosome 2 centromeric PNA probes,
DAKO) were co-denatured at 80C for 3 min and hybridized for
2 h at room temperature in a humidified chamber. Slides were
counterstained with DAPI (Sigma Aldrich) in Vectashield (Vector
Laboratories). Images were captured at a 63X magnification with
an Axio Imager Z2 (Zeiss). ISIS software (MetaSystems) was used
to assess telomere size (defined as ratio between total telomeres’
fluorescence [T] and fluorescence of the centromeres of the two
chromosomes 2 [C]). Data were expressed as T/C%.33 Experiments
were repeated two times and at least 10–15 metaphases were
scored each time.
Detection of Aneuploidy
Chromosome spreads were obtained as described before. Meta-
phases were captured at 633 magnification using an Axio Imager
Z2 microscope (Zeiss). We considered euploidy to be the meta-
phases with 46 chromosomes and aneuploidy to be all of the
metaphases that had a different number of chromosomes. The fre-
quency of aneuploidy was scored in 40 metaphases. Two indepen-
dent experiments were performed.
Chromosome Condensation Assay
After 30min incubation with 30 mMCalyculin-A (Wako), a 28 min
incubation at 37Cwith hypotonic solution (75mMKCl), and fix-
ation in freshly prepared Carnoy solution (3:1 v/vmethanol/acetic
acid), chromosome spreads were obtained. Slides were stained
with DAPI (Sigma Aldrich) in Vectashield (Vector Laboratories),
and an Axio Imager Z2 microscope (Zeiss) was used. To analyze
the frequency of chromosomal condensation, we counted the
number of metaphases in 150 nuclei per sample in two indepen-
dent experiments.
Methylome Profiling
We assessed the DNA methylation levels of one adult and five pe-
diatric affected individuals through the use of the Infinium Hu-
man Methylation EPIC BeadChip assay (Illumina), which allows
comprehensive genome-wide coverage, and genomic DNA ex-
tracted from leukocytes. Methylation levels were measured as
beta values, percentages of methylation at each CpG site, and
ranged from 0 (i.e., no methylation) to 1 (full methylation). Raw
data were processed with the bioconductor package ChAMP34
and the default parameters were used for filtering low-quality sig-
nals and normalizing data. Methylation profiles were compared
with those obtained from a series of 35 healthy adultmale controlsThe Americanof European descent; these included 31 individuals selected from a
European cohort study (average age 5 SD: 56.1 5 7.4 years).35
Unsupervised multidimensional scaling (MDS) analysis was
used, and the 1,000 most variable probes among samples were
taken into account. Statistical analyses were conducted with R
software (v. 3.5.0). We performed gene and pathway enrichment
analyses of the differentially methylated probes by using the
Gene SeT AnaLysis online tool36 on the associated genes. Func-
tional annotation was carried out bymeans of GO terms including
biological processes, molecular functions, and cellular compo-
nents classes. Pathway analysis was performed using KEGG. Statis-
tical significance was assumed at 0.05 following multiple testing
adjustment (FDR).Results
Spectrum ofHIST1H1EMutations and Associated Clinical
Features
Using whole-exome sequencing (WES), we identified a
novel de novo HIST1H1E frameshift variant, c.441dupC
(p.Lys148Glnfs*48), in an adult individual with hypotri-
chosis, cutis laxa, and ID (S1) (Figure 1A). Mutation anal-
ysis performed on primary skin fibroblasts and hair bulb
epithelial cells from the affected individual supported
our hypothesis of a germline origin of the frameshift.
The variant had not been reported in ExAC/gnomAD,
and this variant affected a relatively large and highly
conserved portion of the encoded protein. In the subject,
WES data analysis excluded the presence of other func-
tionally relevant variants compatible with known Mende-
lian conditions on the basis of the expected inheritance
model and clinical presentation. Through networking
and a GeneMatcher search,37 we identified 12 additional
individuals with similar de novo frameshift HIST1H1E mu-
tations (Figure 1B, Table 1). All changes were short out-of-
frame indels resulting in almost identical shorter proteins
that contained a shared divergent C-terminal tail
(Table S1); these results were consistent with previous
reports.19,20,38,39 None of the frameshifts had been
reported in gnomAD, all were predicted to dramatically
impact protein function, and two of them had already
been reported in ClinVar as disease-causing mutations
(Table 1).
We analyzed the clinical records of the 13 identified sub-
jects (S1 to S13) and collected the information available for
the seven previously published individuals (S14 to S20). All
subjects had variable developmental delay (DD)/ID and a
distinctive facies characterized by bitemporal narrowing
(in 100% of individuals), a prominent forehead (93%),
and a high anterior hairline (88%) as main features, which
were reminiscent of Pallister-Killian syndrome (MIM:
601803) (Figure 1A). In four children, Sotos syndrome
(MIM: 117550) had been suggested, andWeaver syndrome
(MIM: 277590), Simpson-Golabi-Behmel syndrome (MIM:
312870), and Pallister-Killian syndrome had been sus-
pected in single cases (Table S2). Half of the individuals
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Table 1. Frameshift HIST1H1E Mutations Identified in This Study
Nucleotide Changea gnomAD ClinVar Amino Acid Change Domain CADDb Number of Cases Origin
c.408dupG - - p.Lys137Glufs*59 C-terminal tail 34 1 de novo
c.414dupC - - p.Lys139Glnfs*57 C-terminal tail 35 2 de novo (1)
c.425_431delinsAGGGGGTT - - p.Thr142Lysfs*54 C-terminal tail 31 1 de novo
c.425delinsAG - - p.Thr142Lysfs*54 C-terminal tail 29 1 undetermined
c.430dupG - reported p.Ala144Glyfs*52 C-terminal tail 26.8 2 undetermined
c.441dupC - reported p.Lys148Glnfs*48 C-terminal tail 34 4 de novo
c.447dupG - - p.Ser150Glufs*46 C-terminal tail 34 1 de novo
c.464dupC - - p.Lys157Glufs*39 C-terminal tail 35 1 de novo
Nucleotide numbering reflects cDNA numbering with 1 corresponding to the A of the ATG translation initiation codon in the HIST1H1E reference sequence
(RefSeq: NM_005321.2, NP_005312.1).
aClinVar submission IDs: c.408dupG, SCV000925231; c.414dupC, SCV000925232; c.425_431delinsAGGGGGTT, SCV000925233; c.425delinsAG,
SCV000925234; c.430dupG, SCV000925235; c.441dupC, SCV000925236; c.447dupG, SCV000925237; and c.464dupC, SCV000925238.
bCADD v1.4.craniofacial appearance was characterized by hypertelor-
ism (91%), downslanted palpebral fissures (67%), a broad
nasal tip (83%), and low-set and posteriorly rotated ears
(57%). Forty-three percent of subjects showed small,
widely spaced teeth. Skin hyperpigmentation was present
in one-third of individuals. Neonatal problems included
hypotonia, feeding difficulties, failure to thrive, jaundice,
congenital hypothyroidism, andmicrognathia. Three indi-
viduals showed single palmar creases possibly related to
prenatal hypotonia. Finger abnormalities included short
fourth metacarpals, camptodactyly, fifth finger clinodac-
tyly, brachydactyly, and broad and low-set thumbs. Toe ab-
normalities included long halluces, broad toes, and fifth
toes overlapping fourth toes. Two individuals had pectus
excavatum. Growth parameters at birth were unremark-
able. At last evaluation, only one subject (S10) hadmacros-
omy (>3.65 SD), and 12 individuals (63%) had a large head
circumference (>þ2.0 SD), including two children with
relative macrocephaly at the age of 4 years. DD was present
in all individuals. They were mildly to moderately intellec-
tually disabled. Fourteen individuals had speech delay, and
gross motor delay was a common feature. In young indi-
viduals, hypotonia and a stiff, clumsy, and uncoordinated
gait were relatively common findings. The 49-year-old in-
dividual (S1) had gait ataxia. Behavioral features included
ADHD (two individuals), autistic features (five individ-
uals), and psychotic episodes (one individual). One child
had focal seizures in early childhood, and another child
was treated for recurrent status epilepticus. Brain MRI re-
vealed aspecific abnormalities, including mild inferior ver-
mian hypoplasia, delayed myelination, partial agenesis of
the corpus callosum, and mild to moderately enlarged
third and lateral ventricles. Five individuals presented
with mild hearing loss. Visual problems included hyper-
metropia, myopia, astigmatism, and strabismus. Sixty
percent of the individuals had feeding or eating difficulties,
ranging from satiety problems at younger ages to problems
with swallowing fluids or learning to eat solid food. One498 The American Journal of Human Genetics 105, 493–508, Septemchild was fed by G-tube at the age of 2.5 years. She had gas-
tro-esophageal reflux disease and rumination disorder.
Other remarkable features in this cohort included pancyto-
penia accompanying systemic lupus erythematosus in the
oldest individual. A summary of the major features is re-
ported in Table 2, and a more detailed description for
each subject is available in Table S2.
Notably, the oldest individuals of the present cohort (S1
and S3) and two previously reported subjects (S15 and S17)
had facial appearances compatible with a much more
advanced age. When we evaluated the clinical presenta-
tion of the entire cohort of affected individuals, including
those previously reported, we noticed an overrepresenta-
tion of features that are generally less common for individ-
uals in this age group but more commonly found in
elderly individuals. These features included hypotrichosis,
ptosis, cutis laxa, hyperkeratosis, skin hyperpigmentation,
dry skin, nail abnormalities, hearing loss, cataracts, dia-
betes mellitus, and osteopenia (Table S3). One girl was
diagnosed with childhood hypophosphatasia (osteopenia
and advanced bone age that was investigated after she pre-
sented with multiple small stress fractures of the lower
limbs). Three other children also had advanced bone age.
A fifth child had multiple fractures after minor trauma.
Several children had dental problems including missing
permanent teeth and small, fragile teeth.
Functional Characterization of HIST1H1E Mutations
Based on the unique narrow spectrum of mutations, we
hypothesized a specific disruptive impact on HIST1H1E
function as a consequence of the frameshift. Haploinsuffi-
ciency was considered unlikely because endogenous
HIST1H1E mRNA levels from two unrelated affected sub-
jects (S1, aged 49 years, and S2, aged 4 years) were compa-
rable to those of controls, and transient transfection
experiments involving Xpress-tagged HIST1H1E con-
structs in COS-1 cells documented an increased stability
of the mutant proteins compared to the wild-type proteinber 5, 2019
Table 2. Summary of the Clinical Features Occurring in Subjects
Carrying de novo HIST1H1E Frameshift Mutations
Clinical Features Frequencya
DD/ID 18/18b (100%)
motor delay 12/12 (100%)
walking independently, range (mean), months 15–66 (31)
speech delay 14/14 (100%)
hypotonia 11/15 (73%)
autistic features 5/14 (36%)
Craniofacial Features 19/19 (100%)
macrocephaly 12/19 (63%)
scaphocephaly 6/11 (54%)
sparse hair 6/12 (50%)
high anterior hairline 14/16 (87%)
prominent forehead 13/14 (93%)
hypertelorism 10/11 (91%)
downslanted palpebral fissures 8/12 (67%)
full nasal tip 10/12 (83%)
low set ears 8/14 (57%)
Aging Appearence 20/20 (100%)
skin hyperpigmentation 5/15 (33%)
hypotrichosis 6/20 (30%)
skin hyperpigmentation 5/20 (25%)
nail abnormalities 6/20 (30%)
dental problems 6/20 (30%)
advanced bone age 4/20 (20%)
Other 9/15 (60%)
feeding or eating difficulties 9/15 (60%)
hearing loss 5/14 (36%)
strabismus 8/15 (53%)
aThe reported cohort includes 13 presently described subjects and seven pre-
viously reported cases.
bSubjects showed variable ID: five mild, nine moderate, and two severe. In two
cases, the severity of ID was unspecified.(Figure S1). Furthermore, confocal microscopy analysis
performed in transiently transfected HeLa cells showed
proper nuclear localization and stable binding to chro-
matin of the tested mutants (Figure S2). These data, along
with the finding that a mutant allele expressing the third
open reading frame at an equivalent position of the C ter-
minus (this allele does not occur in affected individuals)
was characterized by compromised chromatin binding,
indicating loss of function (Figure S2), strongly suggested
a dominant negative or neomorphic effect as the mecha-
nism of disease.
H1 linker histones are core chromatin components, and
they bind to short DNA segments at the entry and exit sitesThe Americanon the surfaces of nucleosomes, stabilizing their structure
and regulating chromatin folding.4 The C-terminal tail of
H1 histones contains a number of serine/threonine resi-
dues that undergo reversible phosphorylation, modulating
the dynamics of chromatin compaction; these residues are
lost in disease-associated HIST1H1E mutants. Of note,
although partial phosphorylation of the C-terminal tail
allows chromatin relaxation during interphase, full phos-
phorylation is required for maximal chromatin condensa-
tion during mitosis.4,12 To assess chromatin compaction,
we performed a single-cell gel electrophoresis (SCGE) assay
in primary fibroblasts from subjects S1 and S2. Increasing
run times allowed DNA loops to extend under the electro-
phoretic field and showed significantly more nucleoid
relaxation in fibroblasts from affected individuals than
in control cells; these results were quantified as ‘‘tail
moment’’ values (Figure 2A). Because chromatin compac-
tion is associated with a specific pattern of histone modifi-
cations, including methylation of histone H3 at specific
lysine residues,40 the methylation profile of histone H3
was assessed in the two fibroblast lines. Consistent with
the SCGE data, a decrease in H3K4me2, H3K9me3, and
H3K27me3 staining was documented by immunofluores-
cence analyses (Figure 2B). In line with these findings,
reduced levels of HP1b, a member of the HP1 family
mediating heterochromatinization by binding to methyl-
ated H3K9, and whose level is reduced in cells with a
defective heterochromatin state,41 was also observed
(Figure 2C). Finally, a caliculin-induced premature chro-
mosome condensation assay documented significantly
fewer condensed chromosomes in fibroblasts from affected
individuals (11.3% of analyzed cells) than in control cells
(19.6%) (p < 0.01, c2 test). Overall, these data indicated a
more relaxed state of chromatin in cells expressing the dis-
ease-causing HIST1H1E mutants.
Methylome Profiling
Because altered chromatin condensation is expected to
impact DNA methylation,42 we used a genome-wide
methylation profiling analysis to investigate perturbations
at the epigenome level. To this end, Infinium Methylatio-
nEPIC BeadChip profiling was used for comparing a subset
of DNA samples obtained from leukocytes of six affected
individuals to samples from a control group composed of
35 healthy individuals of European descent. When the
entire set of assayed target probes is considered, the anal-
ysis did not highlight a substantial change in methylation
pattern (data not shown). However, MDS analysis was car-
ried out taking into account the information associated
with the 1,000 most differentially methylated probes
among all samples (independently from their group classi-
fication), and the results indicated clear-cut divergence be-
tween the methylation profiles of healthy controls and
those of affected individuals, the latter clustering accord-
ing to the ages of the individuals (Figure 2D). Among these
informative probes, 170 differentially methylated CpGs
were located within the UCSC CpG islands (from 200 bpJournal of Human Genetics 105, 493–508, September 5, 2019 499
Figure 2. SCGE Assay, Immuno-Fluorescence Studies, and Methylation Profiling Analysis
(A) Increasing electrophoresis run times (20, 40, and 60 min) highlighted significant differences in relaxation of DNA supercoiling be-
tween fibroblasts from control and from affected individuals. DNAmigration was quantified as Tail moment values, which are defined as
the products of the tail length and the fraction of total DNA in the tail (upper panel). Nucleoids of cells from subjects S1 and S2 showed a
significantly higher Tail moment value (*p < 0.05, **p < 0.01; two-tailed Student’s t test). For each experimental point, at least 75 cells
were analyzed. Values are mean 5 SEM of three independent experiments. Representative images of nucleoids from fibroblasts from
control and affected individuals at each run time are shown (lower panel).
(B) Confocal laser scanning microscopy (CLSM) observations document overall decreased amounts of H3K4me2, H3K9me3, and
H3K27me3 staining (green) in S1 cells compared to control cells. Nuclei were stained with DAPI. Images are representative of >200
analyzed cells. Scale bars represent to 8 mm.
(C) Fibroblasts from subject S1 show a decreased amount of HP1b compared to control cells (WT). Cells were stained with antibodies
against HP1b (red) and HIST1H1E (H1.4) (green); DNA are DAPI-stained (blue). Scale bars represent 7 mm.
(legend continued on next page)
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Figure 3. Proliferation Assay and Cell-
Cycle Progression
(A) Cells were seeded at 200,000 cells/well
in a six-well plate and incubated a 37C.
Cell numbers (mean of three replicates 5
SD) were counted by trypan blue exclusion
assay after four and seven days. A signifi-
cantly decreased proliferation rate was
observed in the fibroblast lines from the
two unrelated affected individuals (S1
and S2). Cells from subject S1 show a per-
manent cell growth arrest.
(B) Cell cycle phases of S1/S2’s (right) and
control (left) fibroblasts as measured by
BrdU incorporation and propidium iodide
(PI) flow cytometry analysis. The upper
box identifies cells incorporating BrdU
(S phase), the lower left box identifies
G0/G1 cells and the lower right box repre-
sents G2/M cells. One of three indepen-
dent experiments is reported with the per-
centage of cells in each cell cycle phase.to 1500 bp from TSS) (Table S4). Kyoto Encyclopedia of
Genes and Genomes (KEGG) and Gene Ontology (GO)
cellular component enrichment analyses revealed a signif-
icant enrichment of genes linked to pathways mainly
related to neurological, immunological, and cell adhe-
sion/membrane function; these represent cellular pro-
cesses relevant to the clinical phenotype of affected
individuals (Table S5). A separate clustering of affected
pediatric individuals from controls was also observed
through the use of a recently defined episignature set,
which successfully profiled 14 developmental disorders
(data not shown);43 this further supports the occurrence
of a specific methylation profile in people with HIST1H1E
frameshift mutations. These findings are in line with those
of previous studies performed in cells with defective his-
tone H1 function, which showed aminor impact on global
DNA methylation compared to controls. Rather, in these
cells, changes involved specific CpGs within regulatory do-
mains of regulated genes,44 indicating that chromatin rear-
rangement in these cells does not globally impact the
methylation status of DNA but instead affects specific sub-
sets of genes and cellular processes.(D) Multidimensional scaling plot of genome-wide methylation analysis using the top 1,000
plot shows the distinct methylation profiles of pediatric (open circles) and adult (S1, dup
compared to healthy controls (filled squares).
(E) DNA damage was induced by 1 or 2 Gy g-ray irradiation. Tail moment values indicate the
measured by SCGE assay immediately after treatment. S1 and S2 fibroblasts showed a higher
p < 0.001; two-tailed Student’s t test). For each experimental point, at least 75 cells were an
independent experiments.
The American Journal of Human GenetHIST1H1E Mutations Cause
Accelerated Cellular Senescence
On the basis of the occurrence of
phenotypic features suggestive of pre-
mature aging and the fact that a more
relaxed compaction of chromatin hasbeen functionally linked to replicative senescence,45 a
feature occurring in progeroid syndromes,46 we hypothe-
sized that the aberrant function of the HIST1H1E mutants
might promote accelerated senescence. To test this hy-
pothesis, we evaluated proliferative competence and
morphological and biochemical markers of cellular senes-
cence. Trypan blue exclusion assay documented a variable
but consistently reduced proliferation rate in cells from
affected individuals (Figure 3A). Of note, a complete prolif-
erative arrest was observed in S1 fibroblasts at relatively
early passages. Consistent with this finding, flow-cytome-
try analysis documented a block in cell-cycle transition
from G0/G1 to S phase (Figure 3B). Compared to control
fibroblasts, those derived from affected individuals were
larger and had a flattened and irregular shape. This was
apparent at early passages and became more pronounced
with passage of cultured cells (Figure S3). Additionally,
compared to age- and passage-matched control cells,
fibroblasts endogenously carrying the HIST1H1E mutant
allele were characterized by a significantly augmented
SA-b-gal activity (Figure 4A), which is an established
marker of cellular senescence.46 Furthermore, enhancedmost variable probes among samples. The
licate) (filled circles) affected individuals,
amount of radiation-induced DNA damage
sensitivity to g-ray irradiation (*p< 0.02, **
alyzed. Values are means 5 SEM of three
ics 105, 493–508, September 5, 2019 501
Figure 4. Defective HISTH1E Function
Results in Altered SA-b-gal Activity and
p53 Expression Level
(A) Representative images (left) and quan-
tification (right) of SA-b-gal activity evalu-
ated on S1 and control (C) fibroblasts at
different culture passages. The significance
was measured by one-way Anova with Tu-
key’s multiple comparison test (*p < 0.01,
**p < 0.0001).
(B) Compared to control cell lysates, fibro-
blast lysates from individuals S1 and S2
showed enhanced TP53 protein levels at
earlier passages. Representative blots (left)
and mean 5 SD densitometry values
(right) of three independent experiments
are shown (*p < 0.05, **p < 0.002; two-
tailed Student’s t test).levels of TP53, whose amount increases during replicative
senescence,47 were observed at early passages (Figure 4B).
These data demonstrate a direct link between aberrant
HIST1H1E function and replicative senescence.
In premature-aging disorders, replicative senescence can
be caused by multiple events, including DNA double-
strand breaks (DSBs), telomere dysfunction and/or acceler-
ated shortening, and lamin defects.48–50 To evaluate the
telomere status, we first performed Q-FISH analysis, which
showed no difference in telomere length between control
cells and fibroblasts from affected individuals (Fig-
ure S4A). Immunofluorescence analysis designed to
identify gH2AX foci, markers of DSBs,51 showed an
increased number of positive cells and foci per cell among
those carrying mutant HIST1H1E compared to control
cells (Figure S4B), indicating increased spontaneous DNA
damage. ImmunoFISH analysis also documented a higher
frequency of co-localization between gH2AX foci and
telomeres in cells from affected individuals than in con-
trol cells (Figure S4C), highlighting the presence of
dysfunctional telomeres in these cells. Fibroblasts carrying
the mutated HIST1H1E allele also showed a higher sensi-
tivity to low doses of g-ray irradiation (Figure 2E), docu-
menting augmented susceptibility to DNA damage. These
findings suggest that the proliferative arrest and senescent
phenotype of cells expressing the mutant HIST1H1E allele
might result, at least in part, from ineffective DNA repair
and persistent activation of DNA damage response
(DDR) signaling.52,53 To explore this possibility, the frac-
tion of residual DNA damage was evaluated by SCGE assay
post-g-ray irradiation. Kinetics data documented defective
and/or delayed DNA repair of single-strand breaks and
DSBs in mutant fibroblasts compared to control cells
(Figure S5).
Cells carrying LMNA (MIM: 150330) gene mutations
that drive cellular senescence exhibit characteristic
morphological nuclear abnormalities due to altered me-
chanical properties of the lamina,54 a network of struc-502 The American Journal of Human Genetics 105, 493–508, Septemtural filaments that interact with chromatin to partici-
pate in chromatin remodeling and organization as well
as DNA replication and transcription.55–58 Thus, we
explored possible changes in nuclear morphology and
architecture. Immunofluorescence analysis showed aber-
rant lamin A/C morphology in cells that were taken
from affected individuals and induced to divide after
thymidine/nocodazole treatment (Figure 5A). Aberrant
morphology ranged from abnormal nuclear shapes to
nuclear blebbing. Of note, an increased number of
aberrantly shaped nuclei in fibroblasts carrying the
HIST1H1E frameshift was observed at early passages in
cells from affected individuals compared to control cells,
and this difference became more pronounced as passages
increased (p < 0.0000001; two-tails Fisher’s exact test)
(Figure 5B). This feature is reminiscent of changes in nu-
clear shape in progeroid syndromes and confirms the se-
nescent phenotype associated with aberrant HIST1H1E
function.
HIST1H1E Mutations Trigger Nucleolar Instability
Heterochromatin plays a role in maintaining nucleolar
stability and controlling rRNA synthesis,59 and decreased
heterochromatin levels have been associated with nucle-
olar instability and upregulated transcription of rRNA
genes that, in turn, has been suggested to enhance
protein synthesis and contribute to overgrowth and accel-
erated aging.60,61 Besides functioning in ribosome biogen-
esis, the nucleolus is involved in cell-cycle control,62 and
linker histones have been reported to interact with multi-
ple nucleolar proteins that are implicated in various
nucleolar functions.63 On the basis of these consider-
ations, we explored whether HIST1H1E mutations trigger
nucleolar instability. As shown, S1 fibroblasts displayed
fragmentation of the nucleolus, as revealed by loss of
the nucleolar marker nucleolin (Figure 6A), and these
fibroblasts also showed increased 28S rRNA levels and
an increased amount of 18S (Figure 6B); these resultsber 5, 2019
Figure 5. Defective HISTH1E Function Results in Aberrant Nuclear Morphology That Is Exacerbated over Cell-Culture Passages
(A) CLSM analysis was performed in steady-state (left) and synchronized (right) skin fibroblasts induced to divide after being treated with
thymidine/nocodazole and recovered with fresh medium. The panels show an aberrant nuclear morphology in cells from subject S1.
Whereas control cells proceed through mitosis (representative metaphases are shown), S1 fibroblasts fail to progress. Experiments
were carried out at early passages (passage 3). Cells were stained with an antibody against lamin A/C (red) and DAPI (blue). Images
are representative of >200 analyzed cells. Scale bars represent 7 mm.
(B) CLSM analysis was performed on S1 and control fibroblasts seeded at different culture passages. The panels show an aberrant nuclear
morphology at early passages in subject S1’s cells compared to control cells, which were seeded at late passages (passage 16). Percentages
refer to the number of cells with aberrant nuclear morphology. Cells were stained as above. Images are representative of >200 analyzed
cells. Scale bars represent 27 mm.further document the pleiotropic effect of HIST1H1E
mutations. Notably, these findings suggest that besides
affecting nucleolar function, dysregulated rRNA synthesis
driven by HIST1H1E frameshift mutations might repre-
sent the molecular event causally linked to macrosomia,
a recurring feature among young children with this
class of mutations.19,20 This hypothesis is in line with
other observations correlating tissue plasticity to ribo-
somal biogenesis, as documented for the skeletal muscle
mass modulated by seasonal acclimatization in Cyprinus
carpio.64
Aneuploidy Is a Major Feature of Cells Bearing HIST1H1E
Frameshift
Finally, because maximal chromatin compaction is
required for proper chromosomal segregation and aneu-
ploidy is a marker of the chromosomal instability which
characterizes the senescent phenotype, we expected the
occurrence of aneuploidy in cells expressing the disease-
causing HIST1H1E mutants. Indeed, direct count of chro-
mosomes in metaphases revealed a remarkably high
proportion of aneuploidy in early-passage fibroblasts
from S1 (41.2% of analyzed cells), which was significantly
higher even when compared to late-passage control fibro-
blasts (18.9% of cells) (p < 0.01, c2 test).The AmericanDiscussion
Here we show that a specific class of dominantly acting
frameshift mutations affecting the C-terminal tail of
HIST1H1E disrupts chromatin structure and nuclear lam-
ina organization and drives cellular replicative senescence.
By assessing the clinical records of a relatively large cohort
of individuals carrying these mutations, we also show that
this endophenotype is mirrored by features suggestive of
accelerated aging.
HIST1H1E is one of the members of the linker histone
family, whose members function as structural components
of chromatin to control the extent of DNA compaction
and contribute to the regulation of gene expression and
DNA replication, recombination, and repair.4,6,8,44 Linker
histones are encoded by multiple genes in the mammalian
genomes; such genes include paralogs characterized by a
diverse expression pattern during development and hav-
ing either a ubiquitous distribution or an expression
restricted to specific cell types.9,65 Among these, HIST1H1E
has been reported to be expressed ubiquitously at a high
level,65 and similarly to the other replication-dependent
linker histones, HIST1H1E is synthetized during the
S phase to assemble chromatin with newly replicated
DNA.66 As with the other linker histones, the protein isJournal of Human Genetics 105, 493–508, September 5, 2019 503
Figure 6. Defective HIST1H1E Function Results in Nucleolar
Fragmentation and Increased 18S and 28S rRNA Levels
(A) CLSM observations were performed on S1 and control (C)
fibroblasts. Panels show a significant decrease in C3 clone anti-
body staining in S1 fibroblasts, revealing nucleolar fragmentation.
Nuclei were stained with DAPI. Images are representative of >200
analyzed cells. Scale bars represent 9 mm.
(B) Total RNA was extracted from the same amount of S1 and C
cells at different cellular passages. Three ml of total RNAwas loaded
for size separation on 1% agarose gel and stained with ethidium
bromide. Increased amounts (compared to those in control cells)
of both 28S and 18S rRNA codifying for ribosomal subunits are
evident in fibroblasts from subject S1.relatively depleted from active promoters and other regula-
tory regions controlling transcription and enriched in por-
tions of the genome carrying repressive histone marks.6
Notably, previous studies provided evidence that inactiva-
tion of any of this class of histones does not significantly
perturb murine development, which is compromised
only when a concomitant inactivation of multiple sub-
types occurs, resulting in an extensive reduction of these
proteins.10,11 Consistent with this functional redundancy,
our data do not support haploinsufficiency as the molecu-
lar mechanism implicated in pathogenesis (see below) but
point to a specific, dominantly acting effect causing a pro-
found perturbation of multiple cellular processes directly504 The American Journal of Human Genetics 105, 493–508, Septemand indirectly controlled by chromatin remodeling. Such
pleiotropic effects involve genome instability, epigenetic
modifications, inefficient DNA repair ability, improper
chromosome compaction and segregation, and nucleolar
fragmentation, converging toward cellular senescence
and replicative impasse.
Similar to what is observed in progeroid disorders (e.g.,
Hutchinson-Gilford progeria [MIM: 176670], Werner syn-
drome [MIM: 277700], and lipodystrophy syndromes),
the cellular processes affected in the disorder associated
with aberrant HIST1H1E function, link cellular senescence
to premature aging. The clinical profile of the affected indi-
viduals with HIST1H1E mutations, however, differs from
those of individuals with progeroid disorders, and this pro-
file is quite peculiar. The main features are a distinctive
facies characterized by bitemporal narrowing, macroce-
phaly, prominent forehead, high anterior hairline, sparse
frontotemporal hair, hypertelorism, downslanted palpe-
bral fissures, a broad nasal tip, and low-set and posteriorly
rotated ears. DD/ID invariantly occurs, whereas over-
growth, which had been originally reported as a key
feature of the disorder, was not observed in any of the sub-
jects included in this work at last assessment; this suggests
that enhanced growth might represent a feature character-
izing infancy. Although the facial gestalt can help in recog-
nition of the disorder, we noted that no pathognomonic
features can be used for a definitive clinical diagnosis. In
early childhood, a tentative differential diagnosis should
include Pallister-Killian syndrome and mild phenotypes
within the spectrum of Weaver syndrome, Werner syn-
drome, and other progeroid disorders.
Besides documenting the multiple events contributing
to cellular senescence, the present findings provide a
mechanistic model for themultifaceted impact of this class
of HIST1H1E mutations. Our data further document the
specific and narrow spectrum of disease causative muta-
tions affecting this gene. The long, lysine-rich C-terminal
tail of HIST1H1E encompasses multiple regulatory residues
that are substrates for cyclin-dependent kinases, and the
extent of phosphorylation controls the proper compaction
required for chromosome segregation, as well as local chro-
matin decondensation needed to promote DNA transcrip-
tion, replication, and repair. The phosphorylation of this
region during the cell cycle has been theorized to
contribute to the control of the chromatin state by a
twofold process.3,4,12,67 Partial phosphorylation is attained
during interphase (G0–S phase), allowing dynamical chro-
matin relaxation and access to DNA.68–70 On the other
hand, a maximal phosphorylation is attained during
mitosis (M phase), which is considered to be required for
chromatin condensation and segregation of chromosomes
into daughter cells during cell division.71–75 In this
context, the functionally equivalent disease-causing
frameshift events are the only mutations that are predicted
to not significantly affect the capability of the mutant
protein to retain efficient chromatin binding with
concomitant loss of the regulatory sites required forber 5, 2019
modulation of higher-order chromatin architecture.
Consistent with this model, the HIST1H1E truncating var-
iants reported in gnomAD affect regions of the protein that
do not overlap themutational hotspot here defined but are
much more proximal to the N terminus or to the C termi-
nus (Figure S6). The former are predicted to result in trun-
cated proteins with defective binding to chromatin and/or
expected to undergo accelerated degradation, whereas the
latter retain the regulatory serine/threonine residues and
are not expected to have a dominant negative effect. The
complexity by which the C-terminal tail controls
HIST1H1E function, the high stability of these mutants,
and their ability to bind to chromatin strongly support
the possibility of a dominant negative effect of these mu-
tants. However, neomorphism or gain-of-function as
alternative mechanism(s) of disease cannot be ruled out a
priori, and experimentally testing the different models
will require dedicated studies.
Taken together, the present findings provide evidence
that dominantly acting functional dysregulation of a
linker histone causes a complex cellular phenotype
characterized by replicative senescence and results in a
neurodevelopmental disorder characterized by accelerated
aging.Accession Numbers
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Rome) for technical support. This project was supported, in part,
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Figure S1. Disease-causing HIST1H1E frameshift mutations do not affect RNA and protein 
stability. (A) RT-PCR products obtained from total RNA from fibroblasts of affected subjects S1 
and S2 show equal amount of HIST1H1E cDNA, indicating stability of the mutant transcripts, 
which is consistent with the notion that intronless genes generally evade nonsense-mediated RNA 
decay. GAPDH is reported as internal control documenting the same use of template cDNA. (B) 
Chromatograms showing the heterozygous state of the two studied mutations as assayed on cDNA 
obtained from total RNA of fibroblasts from affected subjects S1 and S2. (C) Protein stability was 
assessed in COS-1 cells transiently transfected with wild-type Xpress-tagged HIST1H1E and 
mutants carrying the c.441dupC (p.Lys148Glnfs*48 [K148Qfs*48]) and c.464dupC 
(p.Lys157Glufs*39 [K157Efs*39]) mutations. After transfection (48 h), cells were treated with 
cycloheximide (CHX, 20 μg/ml) for the indicated time or left untreated. Protein levels was assessed 
by immunoblotting, using an anti-Xpress monoclonal antibody. GAPDH levels are shown to 
document equal loading of total proteins from cell lysates. Western blot from a representative 
experiment of three performed is shown. 
 
 
 
 
Figure S2. Disease-causing HIST1H1E mutants display proper subcellular localization and 
stably bind to chromatin. CLSM analyses were performed on HeLa cells transfected with vectors 
expressing Xpress-tagged wild-type HIST1H1E, two selected disease-causing mutants 
(p.Lys148Glnfs*48 [K148Qfs*48] and p.Lys157Glufs*39 [K157Efs*39]), and a HIST1H1E protein 
generated to express the third open reading frame at an equivalent position of the C-terminus 
(p.Lys148Profs*82 [K148Pfs*82]; not occurring in affected subjects). After 48 h from transfection, 
cells were treated with CSK (right) or left untreated (left), fixed, and stained (anti-X-press 
antibody). Nuclei were stained with DAPI (blue). Images show that, similarly to the wild-type 
protein, the disease-causing HIST1H1E mutants stably bind to chromatin. By contrast, the mutant 
carrying the alternative open reading frame was characterized by compromised chromatin binding, 
as shown by its loss of nuclear localization after CSK treatment. Bars correspond to 20 μm. Images 
are representative of > 200 analyzed cells. 
 
 
 
Figure S3. Accelerated cellular senescence in fibroblasts from affected subject S1. Images 
show morphological changes in cells endogenously expressing the heterozygous c.441dupC 
frameshift (p.Lys148Glnfs*48) in HIST1H1E. Morphology of cells rapidly progress from a thin and 
spindle shape to a large, flattened and irregular shape, which is visible since early passages. 
Photographs are at the same magnification (75 µm). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S4. Telomere status and DNA damage sensitivity in fibroblasts from affected subject 
S1.  (A) Q-FISH analysis. Representative image of a metaphase staining by Q-FISH (left). The 
yellow and white arrows indicate the telomeric signal and centromeres of chromosomes 2, 
respectively, which are used as internal reference in each metaphase. The telomere length was 
measured as the ratio between total telomeres fluorescence (T) and fluorescence of centromeres of 
chromosomes 2. The graph (mean ± SEM) shows no differences between control and S1 samples (p 
< 0.05, Mann-Whitney U test) (right). (B) Representative image of nuclei (DAPI) positive for 
H2AX (green), a marker of DSBs (left). The graph shows the frequency of H2AX foci per cell 
(mean ± SEM) (right). A significant increase in the frequency of foci was observed in S1 cells with 
respect to control cells (**p < 0.001; two-tailed Student’s t-test). (C) Representative image of 
nuclei (DAPI) stained for H2AX (green) and Cy3 (telomere-specific probe, red) (left). A 
magnification of telomere-H2AX co-localisation (telomere dysfunction-induced foci, TIF) is also 
shown. The graph (mean ± SEM) shows the frequency of TIFs per cell (right), which occur with 
higher frequency in cells from subject S1 (*p < 0.05). 
 
 
 
 
 
 
 
Figure S5. Defective HIST1H1E function is associated with defective/delayed DNA repair. 
DNA damage was induced by 1 or 2 Gy γ-ray irradiation. Following treatment, cells were incubated 
at 37 °C for 15 or 30 min to allow DNA repair. The percentage of residual DNA damage was 
calculated as follows: [(tail moment at time t after irradiation – basal tail moment)/(tail moment at 
t=0 – basal tail moment) × 100]. A lower/delayed capability to repair single/double strand breaks 
was observed in fibroblasts from affected subjects S1 and S2 compared to control cells (*p <0.02, 
**p < 0.001; two-tailed Student’s t-test). For each experimental point, at least 75 cells were 
analyzed. Values are mean ± SEM of three independent experiments. 
 
 
 
 
 
 
  
 
 
 
 
Figure S6. Truncating variants in HIST1H1E.  Schematic diagram representing the HIST1H1E 
structure, and the position of the disease-causing frameshift mutations identified in this and 
previous studies (below the cartoon, red) and those reported in gnomAD (above the cartoon, green). 
The globular domain is shown in yellow. All disease-causing mutations result in a shorter protein 
with an identical divergent C-terminal tail (the new stop codon is shown below the cartoon, 194*). 
Differently, truncating mutations annotated in gnomAD either affect regions of the protein much 
more proximal to the N-terminus (the majority clustering within the globular domain) or are close 
to the C-terminus, downstream the regulatory serine/threonine residues. While the former are 
predicted to result in highly unstable proteins that likely undergo accelerated degradation and/or 
proteins unable to bind chromatin, the latter are expected to be loss-of-function mutants or behave 
as the wild-type protein, but are not expected to have a dominant negative effect. 
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Table S1. Predicted amino acid sequence of disease-causing frameshifts affecting the C-terminal region of HIST1H1E.    
 
AA Change AA Lenght AA Sequence 
Ref. Seq. 
(NP_005312.1) 
219 
MSETAPAAPAAPAPAEKTPVKKKARKSAGAAKRKASGPPVSELITKAVAASKERSGVSLAALKKALAAAGYDVEKNNSRIKLGLKSLVSKGTLVQTKGTGASGSFKLNKKA 
ASGEAKPKAKKAGAAKAKKPAGAAKKPKKATGAATPKKSAKKTPKKAKKPAAAAGAKKAKSPKKAKAAKPKKAPKSPAKAKAVKPKAAKPKTAKPKAAKPKKAAAKKK* 
p.Lys137Glufs*59  
(S12) 
194 
MSETAPAAPAAPAPAEKTPVKKKARKSAGAAKRKASGPPVSELITKAVAASKERSGVSLAALKKALAAAGYDVEKNNSRIKLGLKSLVSKGTLVQTKGTGASGSFKLNKKA 
ASGEAKPKAKKAGAAKAKKPAGAAKEAQEGDGGGHPQEERQEDPKEGEEAGCSCWSQKSEKPEKGESSQAKKGAQEPSEGQSS* 
p.Lys139Glnfs*57  
(S4, S6) 
194 
MSETAPAAPAAPAPAEKTPVKKKARKSAGAAKRKASGPPVSELITKAVAASKERSGVSLAALKKALAAAGYDVEKNNSRIKLGLKSLVSKGTLVQTKGTGASGSFKLNKKA 
ASGEAKPKAKKAGAAKAKKPAGAAKKPQEGDGGGHPQEERQEDPKEGEEAGCSCWSQKSEKPEKGESSQAKKGAQEPSEGQSS* 
p.Thr142Lysfs*54 
(S3, S9) 
194 
MSETAPAAPAAPAPAEKTPVKKKARKSAGAAKRKASGPPVSELITKAVAASKERSGVSLAALKKALAAAGYDVEKNNSRIKLGLKSLVSKGTLVQTKGTGASGSFKLNKKA 
ASGEAKPKAKKAGAAKAKKPAGAAKKPKKAKGVGHPQEERQEDPKEGEEAGCSCWSQKSEKPEKGESSQAKKGAQEPSEGQSS* 
p.Ala144Glyfs*52  
(S8, S13, S16, S20) 
194 
MSETAPAAPAAPAPAEKTPVKKKARKSAGAAKRKASGPPVSELITKAVAASKERSGVSLAALKKALAAAGYDVEKNNSRIKLGLKSLVSKGTLVQTKGTGASGSFKLNKKA 
ASGEAKPKAKKAGAAKAKKPAGAAKKPKKATGGGHPQEERQEDPKEGEEAGCSCWSQKSEKPEKGESSQAKKGAQEPSEGQSS* 
p.Ala145Glyfs*51  
(S15) 
194 
MSETAPAAPAAPAPAEKTPVKKKARKSAGAAKRKASGPPVSELITKAVAASKERSGVSLAALKKALAAAGYDVEKNNSRIKLGLKSLVSKGTLVQTKGTGASGSFKLNKKA 
ASGEAKPKAKKAGAAKAKKPAGAAKKPKKATGAGHPQEERQEDPKEGEEAGCSCWSQKSEKPEKGESSQAKKGAQEPSEGQSS* 
p.Thr146Hisfs*50  
(S14) 
194 
MSETAPAAPAAPAPAEKTPVKKKARKSAGAAKRKASGPPVSELITKAVAASKERSGVSLAALKKALAAAGYDVEKNNSRIKLGLKSLVSKGTLVQTKGTGASGSFKLNKKA 
ASGEAKPKAKKAGAAKAKKPAGAAKKPKKATGAAHPQEERQEDPKEGEEAGCSCWSQKSEKPEKGESSQAKKGAQEPSEGQSS* 
p.Thr146Aspfs*42  
(S19) 
186 
MSETAPAAPAAPAPAEKTPVKKKARKSAGAAKRKASGPPVSELITKAVAASKERSGVSLAALKKALAAAGYDVEKNNSRIKLGLKSLVSKGTLVQTKGTGASGSFKLNKKA 
ASGEAKPKAKKAGAAKAKKPAGAAKKPKKATGAADPKEGEEAGCSCWSQKSEKPEKGESSQAKKGAQEPSEGQSS* 
p.Lys148Glnfs*48  
(S1, S5, S10, S11, S17, S18) 
194 
MSETAPAAPAAPAPAEKTPVKKKARKSAGAAKRKASGPPVSELITKAVAASKERSGVSLAALKKALAAAGYDVEKNNSRIKLGLKSLVSKGTLVQTKGTGASGSFKLNKKA 
ASGEAKPKAKKAGAAKAKKPAGAAKKPKKATGAATPQEERQEDPKEGEEAGCSCWSQKSEKPEKGESSQAKKGAQEPSEGQSS* 
p.Ser150Glufs*46  
(S7) 
194 
MSETAPAAPAAPAPAEKTPVKKKARKSAGAAKRKASGPPVSELITKAVAASKERSGVSLAALKKALAAAGYDVEKNNSRIKLGLKSLVSKGTLVQTKGTGASGSFKLNKKA 
ASGEAKPKAKKAGAAKAKKPAGAAKKPKKATGAATPKKERQEDPKEGEEAGCSCWSQKSEKPEKGESSQAKKGAQEPSEGQSS* 
p.Lys157Glufs*39  
(S2) 
194 
MSETAPAAPAAPAPAEKTPVKKKARKSAGAAKRKASGPPVSELITKAVAASKERSGVSLAALKKALAAAGYDVEKNNSRIKLGLKSLVSKGTLVQTKGTGASGSFKLNKKA 
ASGEAKPKAKKAGAAKAKKPAGAAKKPKKATGAATPKKSAKKTPKEGEEAGCSCWSQKSEKPEKGESSQAKKGAQEPSEGQSS* 
p.Lys148Profs*82 (frameshift 
not occurring in affected 
subjects) 
228 
MSETAPAAPAAPAPAEKTPVKKKARKSAGAAKRKASGPPVSELITKAVAASKERSGVSLAALKKALAAAGYDVEKNNSRIKLGLKSLVSKGTLVQTKGTGASGSFKLNKKA 
ASGEAKPKAKKAGAAKAKKPAGAAKKPKKATGAATPPRRAPRRPQRRRRSRLQLLEPKKRKARKRRKQPSQKRRPRAQRRPKQLNPRRLNQRPPSPRQPSQRRRQPRK
SRKFLWPTA* 
 
Table S2. Clinical features of the affected subjects with frameshift HIST1H1E mutations.  
 
 
 
  
Subject 1 Subject 2 Subject 3 Subject 4 Subject 5 Subject 6
Previously reported - - -
-
- -
Mutation
cDNA (NM_005321.2) c.441dupC c.464dupC
c.425_431delinsAGGG
GGTT
c.414dupC c.441dupC c.414dupC
Protein change 
(www.mutalyzer.nl)
p.Lys148Glnfs*48 p.Lys157Glufs*39 p.Thr142Lysfs*54 p.Lys139Glnfs*57 p.Lys148Glnfs*48 p.Lys139Glnfs*57
De novo inheritance + + + + + U
Epidemiology
Origin caucasian caucasian caucasian caucasian caucasian african american
Gender male female male female female female
Age (years) at last 
observation
49y 4y 6m 30y 9m 14m 12y 3y
Duration gestation (weeks) U 40w 38w 38w 41w 39w
Pregnancy uneventful late hyperemesis
decreased fetal 
movement
wide ventricles seen on 
ultrasound
uneventful, 
amniocentesis was 
performed
uneventful
Neonatal problems U -
fetal heart 
decelerations. Apgar 4 
and 6, cyanosis at birth, 
intubation for ventilation 
(NICU)
primary cesarean (1st 
pregnancy breech 
position)
-
congenital hypotonia, 
feeding difficulties, 
FTT
Birth Weight, g (SD)
U 3714g (+0.73SD) 3713.8g (+0,4SD) 4470g (+2.75SD) 3150g (-0.41SD) 3573g (+0.45SD)
Birth Length, cm (SD)
U 53.3cm (+1.8SD) 52.1cm (+1SD) U 49.5cm (-0.2SD) 53.3 cm (+1.8SD)
Birth OFC, cm (SD)
U U 35 cm (+0.1 SD) U 33cm (-1.32SD) 35 cm (+0.1SD)
Weight at last observation, 
kg (SD)
U 21 kg (+1.93SD) 59 kg (+0.09SD) 10.3 kg (+1.54SD) 41.6 kg (-0.02SD) 14.1 kg (0.14SD)
Height at last observation, 
cm (SD)
U 111 cm (+1.83SD) 167.2 cm (+0.62SD) 74 cm (+0.56SD) 146.2 cm (-0.74SD) 91.4 cm (-0.96SD)
OFC at last observation, cm 
(SD)
U 53.8 cm (+2.1SD) 60cm (+3.4SD) 50 cm (+3.48SD)
54.9 cm (+1.14SD) 
(+2SD at age 4, while 
length -0,5SD)
49.2 cm (-0.07SD)
Growth
Delay/ ID : mild=1; 
moderate=2; severe=3, 
unspecified
2 1 1 0 1 2
Sitting unsupported (months) U 10 8 8.5 12 6
Walking independently 
(months)
U 16 24
not yet at age 14m, but 
makes steps holding 
table since age 1 year
30 24
Motor delay + + +
seems late but still 
within range
+ +
Speech delay + + + U + +
Hypotonia U - + + - +
Seizures, type and treatment U
childhood focal 
seizures
febrile seizures - - -
Hearing loss + - + - - +
Frequent otitis media U - + - - +
Eye defects U U + - + +
Hypermetropia (H)/
myopia (M)
U - M - H -
Astigmatism U - - - + + - simple hyperopic
Strabismus U - + - + -
 
 
  
Subject 1 Subject 2 Subject 3 Subject 4 Subject 5 Subject 6
Craniofacial features
Coarse face U - - - - -
High hairline + + + + + +
Abnormal hair
sparse hair, 
generalized 
hypopigmentation of 
hair, hypotrichosis
frontal upsweep, thin, 
sparse hair
alopecia totalis (sparse 
frontotemporal hair) and 
sparse eyelashes since 
age 10y; delayed hair 
growth as child; no 
eyebrows until about 
age 4.
sparse hair
thin hair, Widow's 
peak (like father)
-
Prominent forehead + + + + + +
Bitemporal narrowing + U + + U U
Epicanthus/telecanthus epicanthus U U U U U
Downward slant palpebral 
fissures
U (small) + + - (narrow) + (narrow) +
Deepset eyes U U + U U U
Ptosis + - + - - -
Hypertelorism + - U + +++ +
Small/pointed chin U + + + - -
Nasal bridge anomalies narrow nasal bridge wide, low and flat U wide - wide
Upturned nasal tip U + - - - -
Full nasal tip U + + + - +
Thick alae nasi U + + + - +
Short nose U - - - - -
Prominent cheek bones U U + U U U
Smooth philtrum U + U - - -
Broad philtrum U - U - - -
Long philtrum U + U - - +
Mouth abnormalities U thin upper vermillion U thin upper vermillion
accentuated Cupid's 
bow, high palate
-
Micrognathia + U + U U U
Widely spaced teeth U - U U
widely spaced central 
incisors
U
Enlarged tongue U U + - U U
Ear abnormalities low set
thickening of superior 
scaphohelices
low set, upturned ear 
lobes
-
low set, simple helix, 
upturned ear lobes
-
Hand abnormalities
brachydactyly, broad 
thumbs, deep palmar 
crease
-
bilaterally brachydactyly 
(shortening of distal 
phalangeal area), 
unilateral palmar crease
-
tapering fingers, 
slightly shorter 4th 
metacarpals. 
Camptodactyly. 
Palmar erythema, low-
set thumbs
-
Joint hyperlaxity/stiffness U - U U very stiff fingers -
Nail anomalies nail dysplasia -
middle ridges on his two 
thumbnails
- thin and short nails -
Feet abnormalities (flat 
feet, sandal gap,...)
U -
orthopedic insoles, flat 
feet
-
orthopedic insoles, 
stiff feet, plantar 
erythema
-
Toe abnormalities
broad hallux, 
deviation of hallux
broad toes U - long halluces -
RX abnormalities U - - U
osteopenia, advanced 
bone age, multiple 
small stress fractures
-
Other limb abnormalities U - U -
lower limb pitting 
edema, genua valga, 
slight leg lenght 
difference
-
 
  
Subject 1 Subject 2 Subject 3 Subject 4 Subject 5 Subject 6
Other
Skull abnormalities
dolichocephaly 
(scaphocephaly), 
abnormal skull 
ossification
dolichocephaly macrocephaly mild turricephaly scaphocephaly -
Cryptorchidism U - unilateral - - -
Renal abnormalities U U kidney cysts bilaterally U U U
Skin
multiple nevi, skin 
hyperpigmentation, 
cutis laxa
1 hypopigmented 
lesion on the left knee
cutis marmorata when 
young.
-
mild cutis marmorata, 
dry skin, multiple 
lentigines solaris in 
face
-
Scoliosis (mild, severe) U - U - mild mild
Widely spaced/inverted 
nipples
U - U - + -
Cardiac abnormalities - - -
small 'atrial septum 
defect
- -
Pectus excavatum/carinatum
excavatum, scapular 
wings
- U - excavatum -
dentition (normal; pointed; 
delayed prim / delayed 
permanent/missing 
permanent)
U
early loss of primary 
teeth/delayed 
permanent teeth
small, poorly enameled 
teeth
pointed teeth
small, pointed teeth, 
some permanent 
teeth missing, short 
roots
U
sleep problems U
+ (restless sleeper 
and early awake)
U -
'+ (frequently awake 
during night, early 
awake)
-
Laboratory abnormalities
pancytopenia 
(possible 
autoimmune origin), 
autoimmune disorder 
(systemic lupus 
erythematosus), 
congenital 
hypothyroidism
mildly elevated 
creatine (age 2 1/2)
 low hemoglobin (iron 
supplementation 
ongoing)
-
Hypophosphatasia 
(zinc deficiency)
-
Neuroradiology
cerebral ultrasound at 
6m: mild ventricular 
enlargement
MRI brain (at age in months) - approx 2y 6m
CT scan at 4 m of age 
and  6 y normal
- U 9m
MRI brain abnormality U
mild ventricular 
enlargement
U U -
mild inferior vermian 
hypoplasia
Autism/Behavioral 
problems
abnormal behavior, 
psychotic episodes
autism spectrum 
disorder
U U
diminished eye 
contact in childhood 
and socialization 
anomalies
-
Clinical diagnosis/tested for: U
Clinical suspicion of 
Sotos syndrome
NSD1 on WES 
normal, CMA normal
Clinical suspicion of 
Sotos syndrome
NSD1 gene normal. 
FXS, Pallister-Killian 
syndrome, Prader Willi 
syndrome, Smith 
Magenis syndrome 
screening normal 
SNP array normal; WES 
panel overgrowth 
syndromes
Clinical suspicion of 
Sotos syndrome 
NSD1 gene normal
U
 
  
Subject 7 Subject 8 Subject 9 Subject 10 Subject 11 Subject 12 Subject 13
Previously reported - - - - - - -
Mutation
cDNA (NM_005321.2) c.447dupG c.430dupG c.425delinsAG c.441dupC c.441dupC c.408dupG c.430dupG
Protein change 
(www.mutalyzer.nl)
p.Ser150Glufs*46 p.Ala144Glyfs*52 p.Thr142Lysfs*54 p.Lys148Glnfs*48 p.Lys148Glnfs*48 p.Lys137Glufs*59 p.A144Gfs*53
De novo inheritance + U U + + + +
Epidemiology
Origin caucasian asian caucasian caucasian caucasian caucasian caucasian
Gender male male female male female male female
Age (years) at last 
observation
11y 11m 4y 9m 2y 1y 7m 6y 4y 17m
Duration gestation (weeks) 34w at term at term 39w 40+2w 39w 39w
Pregnancy
ultrasound 
diagnosis of 
macrocephaly (32 
weeks)
U U uneventful uneventful uneventful uneventful
Neonatal problems 3 weeks in NICU U U -
Apgar 6-9-9, 
insufflation breaths 
and PEEP. 
Ventilatory 
assistance 4 days 
after birth
-
primary cesarean 
(1st pregnancy 
breech position)
Birth Weight, g (SD)
2600g (-1.75SD) 3400g (0SD) U 4100g (+1.4SD) 3482g (+0.27SD) 3886g (+1.05SD)
3780g (SD 
+0.81SD)
Birth Length, cm (SD)
51 cm (0SD) U U 55 cm (+2.7SD) U 55 cm (+2.7SD) 50.8 cm (+0.59SD)
Birth OFC, cm (SD)
35 cm (+0.1 SD) U U 39cm (+3.0SD) U 35 cm (+0.1SD) 38 cm (SD +1.82SD)
Weight at last observation, 
kg (SD)
37.7 kg (-0.44SD) 21.5 kg (+1.29SD) 13.3 kg (+1.16SD) 15 kg (+2.8SD) 26.2 kg (+1.65SD) 21.5 kg (+2.11SD) 9.995 kg (-0.88SD) 
Height at last observation, 
cm (SD)
139.7 cm (-1.62SD) 109.8 cm (+0.43SD) 86 cm (+0.08SD) 92.5 cm (+3.65SD) 120.2 cm (+0.99SD) 106 cm (+0.64SD) 77.1 cm (-0.93SD)
OFC at last observation, cm 
(SD)
58.8 cm (+3.98SD) 55 cm (+3.53SD) 49.4 cm (+1.07SD) 47.3 cm (+0.41SD)
56 cm (+2.94SD) at 
age 6y 9m
56 cm (+3.68SD) 50.7 cm (+3.19SD)
Growth
Delay/ ID : mild=1; 
moderate=2; severe=3, 
unspecified
2 0 unspecified 2 2 1 2
Sitting unsupported (months) 12 11 U 8 14 9 9
Walking independently 
(months)
30 30 U
not yet at 2y 9m, 
can make steps with 
support
66 15 not yet but crawling
Motor delay + + U + + + +
Speech delay + + U + +  + +
Hypotonia + + U - + + +
Seizures, type and treatment 
single childhood 
seizure
U febrile seizures febrile
recurrent status 
epilepticus, 
valproate treatment
 - -
Hearing loss - U + - - -
bilateral mild to 
moderate 
sensorineural 
hearing loss
Frequent otitis media + U U - - - (two times) -
Eye defects + + U U +
lacrimal duct 
stenosis (operation 
at 1.5y)
+
Hypermetropia (H)/
myopia (M)
M U U - H - M
Astigmatism + U U - - - +
Strabismus - + U - + (exotropia) - -
 
  
Subject 7 Subject 8 Subject 9 Subject 10 Subject 11 Subject 12 Subject 13
Craniofacial features
Coarse face - U U + + + +
High hairline + + U + + + +
Abnormal hair - U U - thin hair - -
Prominent forehead + + + + + + +
Bitemporal narrowing U U U U U U +
Epicanthus/telecanthus U epicanthus epicanthus U U  - +
Downward slant palpebral 
fissures
- + U
+ (accentuated by 
puffy eyelids)
- - +
Deepset eyes U U + U U  + -
Ptosis - U U - - - + (mild)
Hypertelorism + U U + + + +
Small/pointed chin - U U - - - +
Nasal bridge anomalies - wide wide wide wide wide -
Upturned nasal tip - + U - + - +
Full nasal tip + U + + + + +
Thick alae nasi - U U - - + +
Short nose - U U - -  - +
Prominent cheek bones U U U U U - -
Smooth philtrum - U U - - - -
Broad philtrum - U U - - - -
Long philtrum - U U - - - +
Mouth abnormalities thin upper vermillion U U - -
thin upper vermillion, 
thick lower 
vermillion, drooping 
lower lip
thin upper vermillion
Micrognathia U U U U U  - -
Widely spaced teeth - U U + U  + -
Enlarged tongue U U U U U  - -
Ear abnormalities low set U low set low set, protruding - low set, rotated ears
low set, posteriorly 
rotated
Hand abnormalities -
tapering fingers, 5th 
finger clinodactyly, 
bilateral single 
palmar crease
U
tapering fingers, 
broad thumbs
small hands
relatively large 
hands
single transverse 
palmer creases
Joint hyperlaxity/stiffness - U U - - - +
Nail anomalies - U U - - flaky nails -
Feet abnormalities (flat 
feet, sandal gap,...)
- bilateral pes planus U - orthopedic insoles - -
Toe abnormalities -
5th toe overlaps 4th 
toe
U - U relatively large feet overlapping toes
RX abnormalities advanced bone age - U U - advanced bone age scoliosis
Other limb abnormalities - U U - valgus hips - hip dysplasia
 
  
Subject 7 Subject 8 Subject 9 Subject 10 Subject 11 Subject 12 Subject 13
Other hemangioma leg
gastroesophageal 
reflux disease
Skull abnormalities - U U scaphocephaly scaphocephaly U
dolichocephaly with 
patent sagittal suture
Cryptorchidism bilateral U - bilateral - + -
Renal abnormalities U U U U U U U
Skin -
flat hyperpigmented 
patches on 
abdomen and 
thighs (dad 
attributes to post 
viral infection)
U - -
mild cutis laxa in 
abdominal area
-
Scoliosis (mild, severe) - U U - - - mild
Widely spaced/inverted 
nipples
- U U - -  +
Cardiac abnormalities - U U - - atrial septum defect
small atrial septum 
defect
Pectus excavatum/carinatum - U U - -  - -
dentition (normal; pointed; 
delayed prim / delayed 
permanent/missing 
permanent)
crowded teeth U U
small teeth, widely 
spaced
tooth dysgenesia 
with extreme short 
radices of milk 
molars with 4 
elementes missing
early eruption of 
teeth
high arched palate
sleep problems - U U - U - -
Laboratory abnormalities - U U - -  - -
Neuroradiology -
MRI brain (at age in months) 3 y; repeat 5y U U 12 m 5m U 14m
MRI brain abnormality
partial agenesis of 
corpus callosum
periventricular white 
matter abnormality
U arachnoid cyst
cavum septum 
pellucidum
U
Mild prominence of 
the subarachnoid 
fluid spaces
Autism/Behavioral 
problems
ADHD
self-stimulatory 
behaviors
U
stereotypic 
movements with 
hands, rolls with 
eyes when tired
-  - none at 17m
Clinical diagnosis/tested for: U U U
CMA and metabolic 
screening normal
Clinical suspicion of 
Sotos syndrome
NSD1, PTEN and 
EZH2 genes 
normal, FXS normal, 
CMA normal
Clinical suspicion of 
Simpson-Golabi-
Behmel syndrome; 
CMA, metabolic 
screening, FXS and 
gene panel normal
Rasopthay panel 
normal; SNP array 
normal; WES
 
  
Subject 14 Subject 15 Subject 16 Subject 17 Subject 18 Subject 19 Subject 20
Previously reported
Duffney et al. 2018
Takenouchi et al. 
2018
Tatton-Brown et al. 
2017
Tatton-Brown et al. 
2017
Tatton-Brown et al. 
2017
Tatton-Brown et al. 
2017
Tatton-Brown et al. 
2017
Mutation
cDNA (NM_005321.2) c.435dupC c.433dup c.430dupG c.441dupC c.441dupC c.436_458del23 c.430dupG
Protein change 
(www.mutalyzer.nl)
p.Thr146Hisfs*50 p.Ala145Glyfs*51 p.Ala144Glyfs*52 p.Lys148Glnfs*48 p.Lys148Glnfs*48 p.Thr146Aspfs*42 p.Ala144Glyfs*52
De novo inheritance + + + + U + +
Epidemiology
Origin caucasian asian caucasian caucasian U U caucasian
Gender male female female male female female male
Age (years) at last 
observation
10y 21y 13y 15y 6m 4y 3m 1y 10m 8y 6m
Duration gestation (weeks) 38w 36w at term 41w at term 37w 41w
Pregnancy
early delivery 
(maternal car 
accident at 38 
weeks)
U U uneventful U uneventful
complicated by 
exposure to chicken 
pox
Neonatal problems
2 weeks in NICU, 
jaundice, 
micrognathia 
increased muscle 
tone and feeding 
difficulties
U
congenital 
hypotonia
congenital hypotonia, 
feeding difficulties
congenital hypotonia, 
feeding difficulties
hypoglycemia and 
increased muscle 
tone
U
Birth Weight, g (SD)
3200g (-0.3SD) 2876g (+1.6SD) 3580g (+0.47SD) 4750g (+2.4SD) 4790g (+2.62SD) 3250g (+0.8SD) 3740g (+0.78SD)
Birth Length, cm (SD)
49.5cm (-0.2SD) 49cm (+1.4SD) 53cm (+1.65SD) U 57cm (+3.76SD) 49cm (+0.7SD) U
Birth OFC, cm (SD)
U 33.4 cm (+0.9SD) U U U 37cm (+3.3SD) U
Weight at last observation, 
kg (SD)
54.5 kg (+2.66SD) U 48.8 kg (+0.4SD) U 24 kg (+2.45SD) 12 kg (+0.65SD) 33 kg (+1.34SD)
Height at last observation, 
cm (SD)
144.8 cm (+0.96SD) 151.8 cm (-1.74SD) 150.8 cm (-0.8SD) 166.5 cm (-0.6SD) 108 cm (+0.8SD) 85 cm (+0.12SD)
133.2 cm 
(+0.56SD)
OFC at last observation, cm 
(SD)
53 cm (+0.25SD)
54.4 cm (-0.15SD; 
relative 
macrocephaly)
55.8 cm (+1.57SD) 58.7 cm (+2.03SD) 55 cm (+3.78SD) 51 cm (+2.65SD)
59 cm (+4.92SD) at 
age 6,3
Growth
Delay/ ID : mild=1; 
moderate=2; severe=3, 
unspecified
2 3 1 2 unspecified 2 3
Sitting unsupported (months) 9 U U U U U U
Walking independently 
(months)
24 30 U U U U U
Motor delay + U U U U U U
Speech delay + + U U U U +
Hypotonia - U + + + U U
Seizures, type and treatment 
single childhood 
seizure
U U U U U U
Hearing loss - U U U U U -
Frequent otitis media - U U U U U U
Eye defects U cataracts at age 21y U U U U
delayed visual 
maturation
Hypermetropia (H)/
myopia (M)
- U U U U U U
Astigmatism + U U U U U +
Strabismus + + + U U U left amblyopia
 
  
Subject 14 Subject 15 Subject 16 Subject 17 Subject 18 Subject 19 Subject 20
Craniofacial features
Coarse face - U U U U U U
High hairline - + + U U U U
Abnormal hair - U U U U U U
Prominent forehead - U U U U U U
Bitemporal narrowing U U U U U U U
Epicanthus/telecanthus U epicanthus telecanthus U U U U
Downward slant palpebral 
fissures
+ U (short) U U U U U
Deepset eyes U U U U U U U
Ptosis - U U U U U U
Hypertelorism + U U U U U U
Small/pointed chin + U U U U U U
Nasal bridge anomalies low wide U U U U U
Upturned nasal tip - U U U U U U
Full nasal tip - U U U U U U
Thick alae nasi - U U U U U U
Short nose - U U U U U U
Prominent cheek bones U + U U U U U
Smooth philtrum + U U U U U U
Broad philtrum + U U U U U U
Long philtrum + + U U U U U
Mouth abnormalities
accentuated Cupid's 
bow
high-arched, wide 
uvula
U U U U U
Micrognathia + U U U U U U
Widely spaced teeth - U U U U U U
Enlarged tongue U U U U U U U
Ear abnormalities - simple auricles U U U U U
Hand abnormalities
clinodactyly for 5th 
fingers
bilateral 5th finger 
clinodactyly
U U U camptodactyly U
Joint hyperlaxity/stiffness + U U U U U U
Nail anomalies +, nail hypoplasia U U dry, flaky nails U U U
Feet abnormalities (flat 
feet, sandal gap,...)
pes planus U U U U U talipes equi-varus
Toe abnormalities long halluces U U U U U U
RX abnormalities 
multiple small stress 
fractures
U advanced bone age U U U U
Other limb abnormalities - U U U U U U
 
 
 
Subject 14 Subject 15 Subject 16 Subject 17 Subject 18 Subject 19 Subject 20
Other
Skull abnormalities - U U U U U U
Cryptorchidism - U - bilateral U U U
Renal abnormalities U U U U U U U
Skin -
hyperkeratosis, 
multiple lentigines
U
multiple nevi, 
redundant skin on 
palm of hands
U U U
Scoliosis (mild, severe) severe U severe U U U U
Widely spaced/inverted 
nipples
+ inverted nipples U U U U U
Cardiac abnormalities - U U U U U U
Pectus excavatum/carinatum - U U U U U U
dentition (normal; pointed; 
delayed prim / delayed 
permanent/missing 
permanent)
multiple caries U U
major dental 
problems with 
crumbling teeth
U U U
sleep problems 
'+ (staying asleep, 
gets up at night and 
can't go back to 
sleep)
U U U U U U
Laboratory abnormalities U diabetes mellitus U U U U U
Neuroradiology
MRI brain (at age in months) 24m U 4m U U U U
MRI brain abnormality
arachnoid cyst and 
mild hydrocephalus
U
mild ventricular 
enlargement
U U U
thin corpus 
callosum and 
periventricular 
leukomalacia
Autism/Behavioral 
problems
lack of eye contact, 
ADHD, obsessive 
behaviors with 
fixated interest
auditory 
hypersensitivity, 
high pitched voice
U
anxiety disorder 
refractory to medical 
treatment, developed 
phobias
U U
challenging 
behavior
Clinical diagnosis/tested for:
SHANK3 related 
disorder and FXS 
screening normal, 
CMA normal
U U U U
Clinical suspicion of 
Weaver syndrome
U
 
Table S3. Aging signs/features of the affected subjects with frameshift HIST1H1E mutations. The table includes the subjects included in the present study (S1 to 
S13) and those previously reported in the literature (S14 to S20). 
 
 
S1 S2 S3 S4 S5 S6 S7 S8 S9 S10 S11 S12 S13 S14 S15 S16 S17 S18 S19 S20 N 
Age (years) 49 4.5  30.7 1.2 12 3 11.9 4.7 2 1.6 6 4 1.4 10 21 13 15.5 4.2 1.9 8.5 20 
Hypotrichosis Y Y Y Y Y      Y          6 
Skin hyperpigmentation Y     Y   Y        Y  Y    5 
Hyperkeratosis               Y      1 
Dry skin      Y           Y      2 
Cutis laxa Y           Y     Y    3 
Cutis marmorata  Y Y  Y                3 
Nail abnormalities    Y  Y       Y     Y    4 
Dental problems  Y Y  Y       Y  Y   Y    6 
Osteopenia      Y                1 
Limb fractures      Y         Y       2 
Advanced bone age      Y  Y     Y    Y     4 
Joint stiffness      Y        Y Y       3 
Lower limb pitting edema      Y                1 
Hearing loss Y   Y          Y        3 
Cataracts               Y      1 
Ptosis Y  Y          Y        3 
Diabetes Mellitus               Y      1 
Pancytopenia/autoimmune 
disorder (systemic lupus 
erythematosus) 
Y                    1 
 
 
 
Table S4. List of the CpG sites located in the promoter regions (200-1500 bp from transcription start sites, 
TSS) of genes found to be differentially methylated in affected individuals with HIST1H1E mutations and 
controls.  
 
IlmnID CHR MAPINFO UCSC RefGene Name UCSC RefGene Group
mean 
controls
mean 
Pt1
mean other 
patients
cg25880954 1 47900630 MGC12982;FOXD2 TSS1500;TSS1500 0.78 0.91 0.81
cg04863005 1 59043208 TACSTD2 TSS200 0.39 0.09 0.31
cg15100762 1 66516476 LOC101927139;PDE4B;PDE4B;
PDE4B;PDE4B;PDE4B
TSS200;Body;Body;Body;Body;
Body
0.85 0.93 0.95
cg09408571 1 101003634 GPR88 TSS200 0.63 0.79 0.72
cg06223162 1 101003688 GPR88 TSS200 0.46 0.54 0.43
cg16180556 1 110230269 GSTM1;GSTM1 TSS200;TSS200 0.29 0.28 0.52
cg24506221 1 110230401 GSTM1;GSTM1 TSS200;TSS200 0.24 0.38 0.48
cg20803293 1 110254709 GSTM5 TSS200 0.35 0.27 0.51
cg16810724 1 110752159 KCNC4-AS1;KCNC4;KCNC4;KCNC4 Body;TSS1500;TSS1500;TSS1500 0.62 0.64 0.49
cg06205333 1 112161618 RAP1A;RAP1A TSS1500;TSS1500 0.61 0.82 0.48
cg10185505 1 150335496 RPRD2;RPRD2;RPRD2 TSS1500;TSS1500;TSS1500 0.72 0.54 0.56
cg12650227 1 152572930 LCE3C TSS1500 0.61 0.19 0.56
cg08477332 1 153590243 S100A14 TSS1500 0.35 0.43 0.45
cg23216745 1 154929762 PBXIP1;PYGO2 TSS1500;3'UTR 0.82 0.89 0.90
cg27003165 1 162381929 SH2D1B TSS200 0.52 0.40 0.67
cg13124890 1 162382662 SH2D1B TSS1500 0.49 0.28 0.67
cg01062020 1 162382848 SH2D1B TSS1500 0.32 0.08 0.47
cg19368440 1 164744070 LOC100505795;PBX1;PBX1;PBX1 TSS200;Body;Body;Body 0.32 0.55 0.79
cg07533224 1 205819345 PM20D1 TSS200 0.43 0.52 0.48
cg12898220 1 205819356 PM20D1 TSS200 0.48 0.57 0.51
cg05841700 1 205819383 PM20D1 TSS200 0.36 0.30 0.37
cg11965913 1 205819406 PM20D1 TSS200 0.26 0.25 0.28
cg07167872 1 205819463 PM20D1 TSS200 0.36 0.42 0.34
cg24503407 1 205819492 PM20D1 TSS1500 0.37 0.46 0.40
cg16334093 1 205819600 PM20D1 TSS1500 0.49 0.51 0.53
cg07157834 1 205819609 PM20D1 TSS1500 0.53 0.57 0.62
cg00541777 2 3652840 COLEC11;COLEC11;COLEC11;COLEC11;
COLEC11;COLEC11;COLEC11;COLEC11;
COLEC11;COLEC11;COLEC11
TSS1500;TSS1500;TSS1500;TSS1500;
Body;Body;Body;Body;Body;Body;
Body
0.73 0.66 0.81
cg10326673 2 30669757 LCLAT1;LCLAT1;LCLAT1;LCLAT1 TSS1500;TSS1500;TSS1500;TSS1500 0.23 0.50 0.42
cg15652532 2 30669759 LCLAT1;LCLAT1 TSS1500;TSS1500 0.23 0.52 0.39
cg24521141 2 38744309 LOC101929596 TSS1500 0.78 0.95 0.89
cg05043910 2 99872119 LYG2 TSS1500 0.52 0.53 0.60
cg23122642 2 113992694 PAX8-AS1;PAX8-AS1;PAX8;PAX8;
PAX8;PAX8
TSS1500;TSS1500;Body;Body;Body;
Body
0.61 0.52 0.58
cg21482265 2 113992762 PAX8;PAX8;PAX8;PAX8;PAX8;LOC440
839;LOC654433
Body;Body;Body;Body;Body;Body;
TSS1500
0.67 0.61 0.68
cg19083407 2 113993142 PAX8;PAX8;PAX8;PAX8;PAX8;
LOC440839;LOC654433
Body;Body;Body;Body;Body;Body;
TSS1500
0.59 0.57 0.57
cg08010094 2 139539001 NXPH2 TSS1500 0.52 0.18 0.38
cg19840088 2 149894678 LYPD6B TSS1500 0.60 0.93 0.64
cg20351137 2 177133606 MTX2;MTX2 TSS1500;TSS1500 0.63 0.67 0.49
cg16955800 2 183981465 NUP35 TSS1500 0.34 0.45 0.21
cg20517941 2 201600636 LOC100507140;AOX2P TSS1500;Body 0.22 0.39 0.33
cg21893210 2 220108407 GLB1L;GLB1L;GLB1L 5'UTR;5'UTR;TSS200 0.39 0.49 0.20
cg24061197 2 220108496 GLB1L;GLB1L;GLB1L 5'UTR;5'UTR;TSS200 0.42 0.59 0.27
cg01588581 2 241832900 C2orf54;C2orf54 TSS1500;Body 0.50 0.41 0.55
cg01904194 2 241832904 C2orf54;C2orf54;C2orf54 TSS1500;TSS1500;Body 0.60 0.45 0.62
cg08144588 3 3080327 CNTN4;CNTN4;CNTN4 Body;TSS1500;Body 0.81 0.94 0.75
cg00457450 3 15107267 MRPS25 TSS1500 0.74 0.30 0.38
cg08033130 3 45983597 CXCR6;FYCO1 TSS1500;Body 0.43 0.34 0.56
cg20540428 3 73045686 PPP4R2 TSS1500 0.35 0.20 0.51
cg06085042 3 195425033 MIR570 TSS1500 0.59 0.50 0.66
cg15727583 3 196757701 MFI2;MFI2 TSS1500;TSS1500 0.77 0.97 0.85
cg01132407 4 645781 PDE6B;PDE6B;PDE6B TSS1500;Body;Body 0.65 0.85 0.50
cg19247841 4 48485301 SLC10A4 TSS200 0.11 0.53 0.08
cg19978674 4 57523826 HOPX;HOPX;HOPX;HOPX;HOPX 5'UTR;Body;Body;TSS1500;TSS1500 0.35 0.21 0.64
 
 
 
Table S5. Gene set enrichment analyses of KEEG pathway and GO cellular component terms associated with the 1,000 most differentially methylated probes 
among affected subjects heterozygous for the HIST1H1E frameshift mutations and controls. 
 
GO term Description GO term 
(Cellular Component) 
FDR Gene Symbol 
GO:0098590 Plasma membrane region 5.69e-11 ABCG2;ADORA2A;ANXA2;ARHGEF18;BCR;C2CD5;CDH13;CPEB4;DISC1;DLGAP1;EHD2;EPS8L1;
ERC1;EXOC1; 
FERMT1;ITGB2;KANK1;KCNC1;KCNC4;KCNJ10;KIFAP3;MLC1;MYO1D;NDRG4;NRCAM;NRP1;P2
RX1;PARD3B; 
PDE6B;PKD1L1;PLB1;PRR12;PTH1R;RGS14;SCN10A;SCRIB;SLC1A1;SLCO1B1;STK39;SYNE1;SY
NJ2;TACSTD2;TANC1;ZFYVE19 
GO:0045202 Synapse 5.69e-11 ABR;ADORA2A;APBB2;BCL11A;BCR;CDH13;CPEB4;CPT1C;CYFIP1;DISC1;DLGAP1;DOCK10; 
ERC1;FGFR2;HDAC4;ITSN1;KCNC1;KCNC4;KCNJ10;MAGI2;MDGA1;NCK2;NRCAM;NRP1; 
P2RX1;PDE4B;PHACTR1;PLCB1;PRR12;PTPRN2;RAB6B;RAP1A;RGS14;RPS6KB1;SCN10A;SCRI
B;SDK1; 
SLC2A8;SYN3;SYNE1;SYNJ2;TANC1;UCN3 
GO:0097458 Neuron part 7.07e-11 ADORA2A;APBB2;ARID1B;ASRGL1;BCL11A;BCR;BRSK2;CCSAP;CDH13;CNTN4;CPEB4;CPT1C; 
CROCC;CYFIP1;DISC1;DLGAP1;DOCK10;ERC1;FBXO31;ITSN1;KCNC1;KCNC4;KCNJ10; 
KCNN3;KIFAP3;LMTK2;MAG;MAGI2;MBP;MTPN;MYO1D;MYO3B;NCK2;NFASC;NRCAM;NRP1;P
2RX1; 
PDE4B;PDE6B;PRPH2;PRR12;PTPRN2;RAB6B;RAP1A;RGS14;RPS6KB1;RPTOR;SCN10A;SCRIB;
SLC2A8; 
SYN3;SYNJ2;TANC1;TSHZ3;UCN3 
GO:0042613 MHC class II protein complex 0.001 HLA-DPB1;HLA-DQB1;HLA-DQB2;HLA-DRB1;HLA-DRB5 
GO:0033267 Axon part 0.001 ADORA2A;APBB2;BRSK2;CPEB4;CYFIP1;ITSN1;KCNC1;KCNC4;LMTK2;MAG;MBP; 
MYO1D;NFASC;NRCAM;NRP1;PTPRN2;SYNJ2;TANC1;TSHZ3;UCN3 
GO:0044463 Cell projection part 0.001 ADORA2A;AGBL2;APBB2;BRSK2;C2CD5;CATSPER4;CCSAP;CPEB4;CPT1C;CROCC; 
CYFIP1;DISC1;DNAH9;DOCK10;DUSP22;EPS8L1;FERMT1;ITSN1;KANK1;KCNC1; 
KCNC4;KIFAP3;LMTK2;MAG;MAGI2;MBP;MYO1D;MYO3B;NDRG4;NEDD1;NFASC;NRCAM;NRP1
; 
PDE4B;PDE6B;PKD1L1;PLB1;PRPH2;PTH1R;PTPRN2;RGS14;RPTOR;SYNJ2;TANC1;TSHZ3;UCN
3;WDR66 
GO:0120038 Plasma membrane bounded cell 
projection part 
0.001 ADORA2A;AGBL2;APBB2;BRSK2;C2CD5;CATSPER4;CCSAP;CPEB4;CPT1C;CROCC;CYFIP1;DISC1
; 
DNAH9;DOCK10;DUSP22;EPS8L1;FERMT1;ITSN1;KANK1;KCNC1;KCNC4;KIFAP3;LMTK2;MAG;
MAGI2; 
MBP;MYO1D;MYO3B;NDRG4;NEDD1;NFASC;NRCAM;NRP1;PDE4B;PDE6B;PKD1L1;PLB1;PRPH
2;PTH1R;PTPRN2; 
RGS14;RPTOR;SYNJ2;TANC1;TSHZ3;UCN3;WDR66 
GO:0044304 Main axon 0.003 ADORA2A;KCNC1;MAG;MBP;MYO1D;NFASC;NRCAM;UCN3 
GO:0042611 MHC protein complex 0.003 HLA-DPB1;HLA-DQB1;HLA-DQB2;HLA-DRB1;HLA-DRB5 
GO:0030424 Axon 0.004 ADORA2A;APBB2;BRSK2;CCSAP;CNTN4;CPEB4;CPT1C;CYFIP1;ITSN1;KCNC1;KCNC4;LMTK2; 
MAG;MBP;MTPN;MYO1D;NFASC;NRCAM;NRP1;PTPRN2;SCN10A;SYNJ2;TANC1;TSHZ3;UCN3 
 
PATHWAY: 
KEGG number 
Description FDR Gene Symbol 
hsa04514 Cell adhesion molecules (CAMs) 0.001 CDH4;HLA-A;HLA-C;HLA-DPB1;HLA-DQB1;HLA-DRB1;HLA-
DRB5;ITGB2;MAG;NFASC;NRCAM;NRXN3;SELL 
hsa04940 Type I diabetes mellitus 0.002 HLA-A;HLA-C;HLA-DPB1;HLA-DQB1;HLA-DRB1;HLA-DRB5;PTPRN2 
hsa05330 Allograft rejection 0.008 HLA-A;HLA-C;HLA-DPB1;HLA-DQB1;HLA-DRB1;HLA-DRB5 
hsa05332 Graft-versus-host disease 0.008 HLA-A;HLA-C;HLA-DPB1;HLA-DQB1;HLA-DRB1;HLA-DRB5 
hsa05416 Viral myocarditis 0.008 HLA-A;HLA-C;HLA-DPB1;HLA-DQB1;HLA-DRB1;HLA-DRB5;ITGB2 
hsa05310 Asthma 0.016 HLA-DPB1;HLA-DQB1;HLA-DRB1;HLA-DRB5;PRG2 
hsa05320 Autoimmune thyroid disease 0.024 HLA-A;HLA-C;HLA-DPB1;HLA-DQB1;HLA-DRB1;HLA-DRB5 
hsa05150 Staphylococcus aureus infection 0.026 C3;HLA-DPB1;HLA-DQB1;HLA-DRB1;HLA-DRB5;ITGB2 
hsa04145 Phagosome 0.026 C3;COLEC11;COLEC12;HLA-A;HLA-C;HLA-DPB1;HLA-DQB1;HLA-DRB1;HLA-DRB5;ITGB2 
hsa04650 Natural killer cell mediated 
cytotoxicity 
0.031 HLA-A;HLA-C;IFNAR2;ITGB2;KLRC4-KLRK1;MICA;PPP3R1;SH2D1B;SH3BP2 
 
GO, Gene Ontology; FDR, false discovery rate; KEGG, Kyoto Encyclopedia of Genes and Genomes. 
 
